Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc.    SLDB

SOLID BIOSCIENCES INC.

(SLDB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
3.26(c) 3.29(c) 3.21(c) 3.15(c) 3.08(c) Last
176 835 193 327 2 071 775 448 566 282 547 Volume
-0.91% +0.92% -2.43% -1.87% -2.22% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -87,8 M - -
Net cash position 2020 60,6 M - -
P/E ratio 2020 -1,87x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -111 M - -
Net cash position 2021 179 M - -
P/E ratio 2021 -2,72x
Yield 2021 -
Capitalization 186 M 186 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 121
Free-Float 57,6%
More Financials
Company
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program,... 
More about the company
Notations Surperformance© of Solid Biosciences Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about SOLID BIOSCIENCES INC.
11/20SOLID BIOSCIENCES INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/05SOLID BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
11/05SOLID BIOSCIENCES INC. : Results of Operations and Financial Condition, Financia..
AQ
11/05SOLID BIOSCIENCES : Reports Third Quarter 2020 Financial Results and Provides Bu..
AQ
11/05Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides B..
GL
11/03SOLID BIOSCIENCES : to Host Third Quarter 2020 Financial Results and Business Up..
AQ
11/03Solid Biosciences to Host Third Quarter 2020 Financial Results and Business U..
GL
10/26ULTRAGENYX PHARMACEUTICAL : and Solid Biosciences Announce Strategic Collaborati..
AQ
10/26SOLID BIOSCIENCES INC. : Other Events (form 8-K)
AQ
10/23SOLID BIOSCIENCES INC. : Entry into a Material Definitive Agreement, Results of ..
AQ
10/23ULTRAGENYX PHARMACEUTICAL : and Solid Biosciences Announce Strategic Collaborati..
AQ
10/02SOLID BIOSCIENCES : to Participate in Virtual Fireside Chat at the Chardan 4th A..
AQ
10/02Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th ..
GL
10/01SOLID BIOSCIENCES INC. : Other Events (form 8-K)
AQ
10/01LETTER TO THE DUCHENNE COMMUNITY : FDA Lifts Clinical Hold on IGNITE DMD Clinica..
PU
More news
News in other languages on SOLID BIOSCIENCES INC.

- No features available -

More news
Chart SOLID BIOSCIENCES INC.
Duration : Period :
Solid Biosciences Inc. Technical Analysis Chart | SLDB | US83422E1055 | MarketScreener
Technical analysis trends SOLID BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 4,70 $
Last Close Price 3,08 $
Spread / Highest target 306%
Spread / Average Target 52,6%
Spread / Lowest Target -35,1%
EPS Revisions
Managers
NameTitle
Ilan Ganot President, Chief Executive Officer & Director
Ian Frederick Smith Chairman
Jennifer Ziolkowski Chief Financial Officer & Treasurer
Carl Morris Chief Scientific Officer
Joel Schneider Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
SOLID BIOSCIENCES INC.-29.21%190
GILEAD SCIENCES, INC.-7.83%75 074
VERTEX PHARMACEUTICALS-0.49%56 654
REGENERON PHARMACEUTICALS39.45%55 264
WUXI APPTEC CO., LTD.59.64%39 757
BIONTECH SE214.34%25 644